Collegium Pharmaceutical, Inc.
Every calculator, already run for COLL
Open the full toolkit →You have the numbers on COLL. Get the argument.
A written report on which of these readings actually decide the outcome for Collegium Pharmaceutical, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
7 analysts covering COLLAnalyst Price Target Disagreement for Collegium Pharmaceutical, Inc.
Wall Street's bull case implies +164% from the current price; the bear case implies +89%. A 75% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for COLL
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formu…
COLL — frequently asked
Is COLL a buy right now?
Wall Street's consensus rating on Collegium Pharmaceutical, Inc. is Buy across 7 analysts, with a mean price target of $48.86 (+115% vs. the current $22.77). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is COLL overvalued?
COLL trades at 17.9x trailing earnings, against a DCF fair value of $406 per share. The current price implies -10% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is COLL's next earnings date?
Collegium Pharmaceutical, Inc. is next scheduled to report earnings around Nov 5, 2026. A full COLL research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Collegium Pharmaceutical, Inc.?
Analysts covering Collegium Pharmaceutical, Inc. (COLL) range from a bear-case target of $43.00 to a bull-case high of $60.00, with a mean consensus target of $48.86 across 7 analysts. The spread of $17.00 (75% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Collegium Pharmaceutical, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Collegium Pharmaceutical, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full COLL research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Collegium Pharmaceutical, Inc., in minutes. 3 free reports included with every account — no credit card required.